Situation Analysis — Brian's Case

Section 1 — About This Document

This analysis applies the PD evidence base to one specific patient's clinical profile. Your situation will differ.

This is educational synthesis, not medical advice — clinical decisions belong to Brian and his urologist.

Patient context: Brian is a 41-year-old patient currently on intralesional verapamil for active-phase Peyronie's disease. His most recent documented Doppler ultrasound was performed on March 19, 2026. He reports curvature progression in the weeks since that study. The analysis below reads his clinical profile against the evidence framework presented in the PD Patient Guide. Cross-references to specific Guide sections appear throughout.

Section 2 — Brian's Clinical Profile in Context

Summary table

The four parameters with the most clinically relevant analysis follow as prose. The remaining three (Curvature Type, Curvature Degree, Erectile Function) are adequately summarized by the table; their evidence mapping appears in Section 3 where it informs treatment implications.

2a. Disease Phase — active by the curvature criterion

Brian's pain has reduced from 8-9 to 2-3 over recent months. His curvature has continued to worsen during the same period, including in the last month.

Under the ICSM 2024 framework, disease phase is determined by whether curvature is still progressing — not by pain trajectory and not by elapsed time. The earlier "12-18 months acute phase" framing has been formally abandoned (ICSM 2024: "no universally agreed-upon definition of the acute phase"). A patient whose curvature continues to worsen is in active phase regardless of pain or duration. (See Guide Part 1, "What Peyronie's Disease Is.")

For Brian, the application is unambiguous: ongoing curvature progression places him in active phase. His pain reduction does not change this classification.

This matters because mistaking pain reduction for phase transition is a documented misapplication risk. If Brian — or anyone framing his clinical course — interpreted the falling pain score as a sign of "transitioning to stable," that would invert the evidence-based phase definition. Pain is one symptom; curvature progression is the criterion.

Biographical context: Brian is 41. Grasso 2007 found a 68% surgical rate in PD patients under 50 — an age cohort with more aggressive progression than older patients. This is biographical context, not predictive of Brian's individual course, but it is consistent with the active-phase framing's clinical urgency. (See Guide Part 5 red-flag table: "Just wait and see.")

What this implies for the conversation with his urologist: the active-phase classification narrows the treatment landscape (see Guide Part 4 for the full phase-based decision framework) and rules out surgical options for the time being. Stable-phase classification — the threshold for surgery — requires ≥6 months of confirmed curvature stability, a higher threshold than the 3-month general phase definition (ICSM 2024 Recommendation #18).

2b. Volume / Shape Deformity — patient-noticed, clinically unassessed

Brian reports that the upper 1/3 of his shaft has visibly thinned. This is consistent with hourglass or indentation deformity. His Doppler study did not include formal volume-loss assessment.

The evidence here is counter-intuitive in two directions at once.

On prevalence: Margolin 2018 (n=128) found 65% of PD patients have volume-loss deformities. This is not rare. It is, however, frequently under-assessed and under-documented in routine PD evaluation.

On treatment implications: historical clinical practice tended to treat hourglass deformity as a contraindication or limitation for CCH. The largest published CCH outcomes study (Cahill 2025, n=826, multivariate P=.02) found the opposite: moderate or severe hourglass / indentation deformity predicts 3 to 10 degrees more curvature improvement than absent or mild volume-loss. Patients with these features were excluded from the original IMPRESS trials, but real-world data positions them among the better-responding subgroups.

For Brian, the synthesis is: if his self-noticed thinning is confirmed at formal assessment, he is in the favorable subgroup for CCH response — not a limited-candidacy subgroup as historical assumptions might have suggested. The pattern is also striking on its own terms: the patient noticed what the clinical evaluation did not assess. This is the volume-loss assessment gap visible in one patient's experience. (See Guide Part 1, "Understanding Your Doppler Results — What your Doppler report may NOT cover.")

What this implies for the conversation with his urologist: Brian's self-noticed thinning is information worth bringing to the next visit, with a direct request that volume-loss assessment be performed and documented. The Cahill 2025 finding makes this assessment more, not less, relevant to treatment planning.

2c. Plaque Characteristics — calcification grading absent from the report

Brian's Doppler written report describes plaque location as mid-to-distal shaft. The report does not include calcification grading — neither presence nor absence of calcification is specifically documented.

Two distinct questions follow:

1. Was calcification specifically assessed during the study and not found, or was it not assessed at all? The written report's silence does not distinguish these scenarios. The distinction matters for completeness of the study.
2. Does calcification status affect Brian's treatment options? The evidence here is unambiguous and recent. Cahill 2025 (n=826, P=.37) found no significant association between calcification and CCH treatment failure. Calcification has been historically over-cited as a barrier to CCH; the largest published outcomes data does not support this view. (See Guide Part 3A, "Predictors of CCH Response.")

The practical implication: even if dense calcification is present at follow-up assessment, CCH remains a viable option. The lack of grading in the current report is a documentation gap worth resolving — but the gap does not, by itself, narrow Brian's treatment landscape.

What this implies for the conversation with his urologist: a direct question at follow-up — "Was calcification specifically assessed during my Doppler? If yes, what was the grading, and how does it affect my treatment options?" — closes the documentation gap and gives Brian a complete picture for downstream decisions.

2d. Treatment History — two layers of evidence absence

Brian is currently on intralesional verapamil at 3-month intervals. He has reported curvature progression during this treatment course.

The verapamil evidence base has two distinct gaps in Brian's case, each significant on its own:

Gap 1 — the drug itself. The only double-blind randomized controlled trial of intralesional verapamil for PD curvature (Favilla 2017, n=140) showed exactly zero curvature change in the verapamil arm (0.00° ± 0.00). Every controlled trial of intralesional verapamil for curvature is negative. Positive results appear only in uncontrolled studies. Major guidelines on verapamil are split: AUA "may consider" (Conditional, Grade C, with the evidence called "weak"); CUA recommends (Level 3, Grade C, practice-based); ICSM Conditional ("may reduce curvature in some patients"); EAU recommends against (Level 4). (See Guide Part 3D.)

Gap 2 — the interval. Standard published verapamil protocols use weekly to biweekly intervals. Even the uncontrolled studies that report positive results use these intervals. The 3-month interval Brian is receiving does not appear in any published protocol — controlled or uncontrolled.

These are two distinct evidence absences: a drug with no controlled curvature efficacy AND a schedule that doesn't appear in the published literature. Brian's curvature has progressed during the regimen.

The combination — (a) no controlled efficacy, (b) interval outside published protocols, (c) ongoing progression — is information worth raising explicitly at the follow-up visit. The Guide's Part 5 red-flag table includes "Let's keep going with verapamil at this interval" as a flag worth surfacing if the urologist's response does not engage with the evidence base.

What this implies for the conversation with his urologist: the appropriate question is not whether verapamil is "working" (the evidence does not support that frame) but whether the current regimen is the best use of Brian's treatment time given the available evidence-supported alternatives. That conversation is the substance of Section 3.

Section 3 — Treatment Implications

This section maps Brian's profile onto the Guide's evidence-based treatment framework. The mapping is not a treatment recommendation. It is the set of factors Brian and his urologist can weigh together when discussing options.

Predictor mapping for CCH

Reading Brian's parameters against the Guide's "Predictors of CCH Response" subsection (Guide Part 3A):

Across multiple predictors, Brian's profile aligns with the better-responding subgroups described in the published outcomes data.

Hedge: alignment with favorable predictors is not a guarantee of response. Fewer than half of CCH patients achieve clinically meaningful improvement even within favorable subgroups (IMPRESS phase III: 46% composite responder; Flores 2022: 44% improved, 39% no change, 17% worsened). The Trost-protocol outcomes reported by Cahill 2025 (median 27.5–32.5°) are not standard CCH results — they require the specific Trost protocol, with documented confounds (98% RestoreX use; triple COI). (See Guide Part 3A for the full evidence picture.)

The predictor mapping is information for the conversation with Brian's urologist about whether CCH is a treatment to discuss further — not a verdict that CCH is the right path.

Phase-based options

Brian is in active phase. The Guide's Treatment Options by Phase table (Guide Part 4) is the framework for the forward-looking conversation. Highlights as they apply to Brian:

• CCH — Off-label viable in active phase per the FDA label, but the clinical evidence (Cocci 2020, Cahill 2025) does not support phase as a discriminator of response. The conversation with the urologist would address insurance coverage of off-label use.
• HA — Positive RCT data concentrated in active phase (Favilla 2017, Abdel Fattah 2024). Major guidelines (ICSM 2024, EAU) recommend against routine use outside clinical trials. Pursuing HA would mean knowingly diverging from current major guidelines. Whether this is the right choice for Brian is a conversation about the strength of the evidence relative to the strength of the guideline opposition.
• RestoreX traction — RCT-supported in both phases, no prescription required, no phase restriction in the trial (Ziegelmann 2019). Discuss with urologist whether and how to incorporate.
• Tadalafil daily — Does not prevent curvature progression but supports penile oxygenation; component of the Mayo Clinic oral PD protocol.
• Surgery — Premature in active phase. Surgical eligibility requires ≥6 months of curvature stability per ICSM 2024 Rec #18, which is a higher threshold than the 3-month phase definition. Surgery is off the table until phase classification changes.

On Brian's current verapamil regimen

Given Brian's treatment history (Section 2d), the forward-looking question is about the appropriate use of his treatment time. The verapamil evidence base is summarized in 2d; the broader treatment landscape above describes the alternatives. The conversation with his urologist would address whether to continue the current regimen, modify it (interval, dosage, route), or replace it with an evidence-supported alternative.

Practical factor — out-of-pocket cost

Brian has met his out-of-pocket maximum for the year. This affects the practical decision space: CCH cycles billed under his current coverage would carry minimal additional patient cost, versus the headline ~$15,000–18,000 total cost cited generally. This is a practical factor in the decision, not a clinical one. It is biographical context.

Section 4 — What Brian's Situation Reveals About the System

This section is observational, not evaluative. The patterns visible in Brian's case are documented systemic patterns in PD care; this is one patient's experience reflecting them. It is not an accusation against Brian's urologist. Brian's experience is consistent with patterns the published literature has characterized at scale.

Five gaps surface in Brian's experience:

1. Volume-loss assessment gap

Brian's self-noticed thinning was not formally assessed during his Doppler study. Margolin 2018 (n=128) found volume-loss deformities in 65% of PD patients; the assessment gap is a documented systemic issue, not unique to Brian's case. The Guide's "What your Doppler may NOT cover" section was written for exactly this scenario.

2. Verapamil at an unprecedented interval

The 3-month verapamil interval Brian is receiving has no published evidence base — neither in controlled trials (Favilla 2017 used standard intervals; arm showed zero curvature change regardless) nor in the uncontrolled studies that report positive results (which used weekly to biweekly intervals). The pattern Brant 2023 documented at scale — that 21% of urologists who self-report following AUA guidelines still use explicitly discouraged treatments — is widespread enough that any individual case is more likely to reflect the systemic pattern than to be a unique outlier.

3. Verbal versus written report discrepancy

Brian recalls a verbal comment from Dr. Lamb suggesting reduced blood flow during the Doppler study. The written report shows all vascular parameters as normal. Whatever the source of the discrepancy, the gap between verbal interpretation and written documentation creates uncertainty for any subsequent provider relying on the written record alone. A direct review of the Doppler images at follow-up — not just the written report — is the path to resolution.

4. Phase methodology — pain-resolution-as-stability risk

If pain reduction were treated as a proxy for phase transition, Brian could be incorrectly classified as approaching stable phase. The ICSM 2024 evidence-based definition (curvature progression status) is unambiguous that he is in active phase. The phase-definition teaching contrast described in the Guide's Part 1 (abandonment of "12-18 months acute" framing in favor of progression-based classification) was developed precisely because the older framing led to misclassifications of this kind.

5. Fellowship training as cross-cutting frame

Brant 2023 found that 81% of urologists treating PD have no fellowship training in andrology or sexual medicine. Across every measured evidence-based practice — in-office curvature assessment, duplex ultrasound, CCH use, traction recommendation, volume-loss assessment — fellowship-trained physicians are significantly more likely to apply current evidence (P<0.005 for all). The five gaps in Brian's experience cluster non-randomly: they are the same gaps Brant 2023 identified as more common in non-fellowship-trained PD care. The systemic pattern is the load-bearing observation here; Brian's case is one instance of it.

The five gaps above describe a system of PD care where current evidence does not yet uniformly inform individual clinical decisions. The Guide's Practice Gap report describes this system at the population level. This Situation Analysis shows what it looks like in one patient's experience.

The path forward — for Brian, for any patient — is the conversation with the urologist that the Guide's framework is designed to support. The evidence is the foundation; the clinical decisions belong to the patient and the doctor together.